A Multicenter, Retrospective Analysis of AML Patients | Jan Bewersdorf, MD | ASH 2023

Investigating Prognostic Significance of Malnutrition in AML | Samuel Yates, MD, MS | ASH 2023

Telehealth Program for Older Patients & Decision Preferences in AML | Jane Liesveld, MD | ASH 2023

IDH2 Mutation Allows Myeloid Differentiation | Jane Liesveld, MD | ASH 2023

Addressing Racial and Ethnic Disparities in AML Clinical Trials | Andrew Hantel, MD | ASH 2023

Study on Minimizing Exclusion for AML Patients in Clinical Trials | Andrew Hantel, MD | ASH 2023

Results from Venetoclax Added to CLAD Combo for Older Patients With AML | Tapan Kadia, MD | ASH 2023

Moving to a Fully Oral Drug Combination for Older/Frail AML Patients | Tapan Kadia, MD | ASH 2023

Extending AML Remissions with Hypomethylating Agents and Venetoclax | Tapan Kadia, MD | ASH 2023